BioPharmSignal logoBioPharmSignal

Biotech News

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

Avalo Therapeutics (AVTX)Avalo TherapeuticsFinancing

AVTX (AVTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is avtx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

AVTXAvalo Therapeutics2026-05-05 20:05 EST

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AVTXAvalo Therapeutics2026-05-05 20:01 EST

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

CLDXCelldex Therapeutics2026-04-02 01:48 EST

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

SABSSAB Biotherapeutics2026-03-18 02:46 EST

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

CABACabaletta Bio2026-05-04 10:35 EST

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

CLDXCelldex Therapeutics2026-04-06 14:53 EST

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SABSSAB Biotherapeutics2026-03-19 20:01 EST

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

ANABAnaptysBio, Inc.2026-03-27 13:00 EST

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

KYMRKymera2026-04-09 11:00 EST

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

View all latest news

Avalo Therapeutics

Avalo Therapeutics is a biotechnology company focused on immune-mediated and inflammatory diseases. Its pipeline aims at selective immune pathways and niche inflammation opportunities.

Recent company news

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

AVTXAvalo Therapeutics2026-07-07 11:00 EST

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

AVTXAvalo Therapeutics2026-06-26 11:00 EST

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

AVTXAvalo Therapeutics2026-06-23 11:00 EST

Avalo Therapeutics Appoints Ron Philip to Board of Directors

AVTXAvalo Therapeutics2026-06-16 11:00 EST

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Stock data

Close
19.50 USD
Market cap
733.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States